ArticleBrain and behavior2023
Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry.
Article in Brain and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia.Clinical rheumatology · 2026Article
- Determinants of adherence and safety in fully autonomous home-based transcranial direct current stimulation for fibromyalgia.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- From farm to bedside: Potential of medical cannabis in global health.Complementary therapies in medicine · 2025Review
- Chemogenetic Modulation of Electroacupuncture Analgesia in a Mouse Intermittent Cold Stress-Induced Fibromyalgia Model by Activating Cerebellum Cannabinoid Receptor 1 Expression and Signaling.Life (Basel, Switzerland) · 2025Article
- Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry.International clinical psychopharmacology · 2025Observational
- UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility-Associated Chronic Pain.ACR open rheumatology · 2025Article
- Predicting therapy dropout in chronic pain management: a machine learning approach to cannabis treatment.Frontiers in artificial intelligence · 2025Article
- UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia.PLOS mental health · 2025Article
- Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: A systematic review.Exploratory research in clinical and social pharmacy · 2024Review
- Validation and cutoff score for the single-item sleep quality scale.Sleep & breathing = Schlaf & Atmung · 2024Article
- The Elusive Truth of Cannabinoids for Rheumatic Pain.Current rheumatology reports · 2024Review
- Illicit Cannabis Use to Self-Treat Chronic Health Conditions in the United Kingdom: Cross-Sectional Study.JMIR public health and surveillance · 2024Article
- Article
- Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry.Brain and behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze changes in health-related quality of life and incidence of adverse events of those prescribed cannabis-based medicinal products (CBMPs) for fibromyalgia.
methodsPatients treated with CBMPs for a minimum of 1 month were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in validated patient-reported outcome measures (PROMs). A p-value of <.050 was deemed statistically significant.
resultsIn total, 306 patients with fibromyalgia were included for analysis. There were improvements in global health-related quality of life at 1, 3, 6, and 12 months (p < .0001). The most frequent adverse events were fatigue (n = 75; 24.51%), dry mouth (n = 69; 22.55%), concentration impairment (n = 66; 21.57%), and lethargy (n = 65; 21.24%).
conclusionCBMP treatment was associated with improvements in fibromyalgia-specific symptoms, in addition to sleep, anxiety, and health-related quality of life. Those who reported prior cannabis use appeared to have a greater response. CBMPs were generally well-tolerated. These results must be interpreted within the limitations of study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.